A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream

Exclusion Criteria

• •Current diagnosis of unstable forms of psoriasis
• •Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis vulgaris
• •Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the treatment areas
• •Planned exposure to either natural or artificial sunlight
• •History of hypersensitivity to any component of the test product or reference product
• •Current or past history of hypercalcemia, vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
• •Systemic treatment with biological therapies
• •Use of systemic treatments that suppress the immune system and other systemic chemotherapeutic antineoplastic therapy within 4 weeks prior to the baseline visit and during the trial
• •Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial;
• •Use of topical treatments, except for emollients and non-medicated shampoos, with a possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline
• •Clinical signs of skin infection with bacteria, viruses, or fungi
• •Known Human Immunodeficiency Virus (HIV) infection
• •Any chronic or acute medical condition that may pose a risk to the safety of the subject, or may interfere with the assessment of safety or efficacy in this trial